in response to pertinent environmental exposures.
Additionally, it is impossible to sample all relevant tissues involved in disease pathogenesis in human populations. To make direct connections between exposure-induced epigenetic changes and health outcomes, it is therefore critical to determine whether epigenetic alterations are conserved across tissues in such a way that easily sampled surrogate tissues could be used to assess the impact of environmental exposure on diseaserelevant but inaccessible target tissues ( Table 1) . The correlation between
The NIEHS TaRGET II Consortium and environmental epigenomics
The human reference epigenome maps generated by consortia, such as the Roadmap Epigenomics Project and the International Human Epigenome Consortium 6, 7 , set the stage for understanding cell-type-specific epigenetic patterns and their dysregulation in disease. However, a similar understanding is lacking of how epigenetic patterns are perturbed by environmental exposures and, in turn, influence susceptibility to environmental diseases. Thus, a major challenge for the environmental health community is to elucidate the mechanisms responsible for epigenome perturbation that drive pathogenesis of chronic diseases 
As part of its mission, the TaRGET II Consortium will provide the scientific community with a plethora of highresolution, integrative epigenome profiles in response to environmental exposure. Raw sequencing data will be quality-controlled and processed using state-of-the-art metrics and pipelines developed by the Consortium for each experimental assay. Furthermore, each file will be densely annotated with multiple layers of informative metadata that will enable comparisons across experiments and studies. The Consortium will facilitate integrative analysis through the development of software and algorithms, such as tools to model correlated epigenome changes between target and surrogate tissues or to transfer epigenomic signatures from mouse to orthologous human (epi)genomes. Like the data, these tools will be publically available to support future complementary analyses by the environmental health research community.
Descriptions of the consortium and its goals and protocols detailing target and surrogate tissue collection, epigenomic assays, and exposure paradigms are available at the consortium website (http:// targetepigenomics.org). Additionally, raw and processed data sets will be publicly accessible through a data portal created by the Data Coordination Center, which will offer tools for in-browser analysis and visualization of data sets, including links to the Washington University Epigenome Browser 8 .
The TaRGET II Consortium will greatly advance our knowledge of the epigenetic mechanisms linking environmental exposure to disease, how they are influenced by the timing and dosage of exposure, and their persistence across the life course. Specifically, the integrative data sets we generate will determine the utility of surrogate tissues to detect epigenomic changes in tissues that are disease-relevant but inaccessible in humans, facilitating future human-population-based studies. exposure-induced epigenetic alterations in target and alterations in surrogate tissues is currently unclear and may not be straightforward, as it may depend on the normal epigenetic landscape of the tissues, the timing, route, and dose of exposure, as well as other variables. Determining the utility of surrogate tissue epigenomic analyses will enable more effective use of population-based studies to make connections between exposure, epigenetic changes, and the development of disease. Furthermore, it remains to be elucidated if cessation or elimination of pertinent exposure that may result in reversal of phenotype is associated with changes in the epigenome.
The TaRGET II Consortium takes advantage of next-generation sequencing technologies to produce epigenomic maps resulting from environmental exposures, interrogating a broad class of epigenomic features (DNA methylation, histone modifications, and chromatin accessibility) and transcriptomic alterations (RNAseq) in both target tissues and cells and surrogate tissues and cells under well-defined exposure paradigms (Fig. 1) . Across the consortium studies, target and surrogate tissues will be harvested over the life course following perinatal, peri-adolescent, or adult exposure to arsenic, lead, bisphenol A (BPA), tributyltin (TBT), the phthalate di-2-ethylhexyl phthalate (DEHP), the dioxin tetrachlorodibenzo-p-dioxin (TCDD), or air pollution in the form of particulate matter <2.5mm (PM 2.5 ) ( Table 1) . These tissue-and exposure-specific epigenomic maps will be produced by five consortium groups across the country (data production centers) and supported by a data coordination center, which will coordinate experimental and analytical efforts to maximize consistency, data quality, and overall coverage of the exposure reference epigenomic landscape. Collectively, the consortium will determine changes in target tissues and cells with those of surrogate tissues and cells to identify predictive locus-specific or genome-wide epigenetic alterations, and to dissect the epigenomic marks that precede and follow development of the phenotype.
The consortium will also investigate a variety of factors, including timing of exposure and gender, that may in turn influence whether environmentally induced epigenetic changes occur and, additionally, to what extent these changes are conserved across tissues or persist throughout the lifespan. These will ultimately provide the context with which to interpret the utility and admissibility of surrogate tissues as representative of changes that occur in target tissues (Fig. 1) . Together, the TaRGET II research program will enhance our understanding of the relationship between exposure-induced perturbations of epigenetic marks in target versus surrogate tissues; determine exposure conditions and life course events where surrogate-tissue epigenetic biomarkers are useful; and aid in the design and interpretation of human environmental health studies.
Key to developing a conceptual framework that describes the impact of specific environmental exposures on epigenetic marks in target and surrogate tissue and cell types, and how the conservation of epigenomic signatures is influenced by variables such as timing of exposure, will be the production of comprehensive, high-resolution, integrative epigenome maps for both target and surrogate tissues. Importantly, delivery of environmental epigenomic data sets generated by the TaRGET II Consortium to the broader scientific community will facilitate further data analyses by integrating additional data from specific target-surrogate pairs and for different epigenetic marks, as well as promoting ancillary studies to develop data on the functional impact of these epigenetic alterations. 
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